# Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome

> **NCT03363035** · PHASE4 · COMPLETED · sponsor: **Second Xiangya Hospital of Central South University** · enrollment: 2055 (actual)

## Conditions studied

- Acute Coronary Syndrome
- Myocardial Infarction
- Myocardial Ischemia
- Unstable Angina

## Interventions

- **DRUG:** Rivaroxaban 2.5 mg
- **DRUG:** Rivaroxaban 5 mg
- **DRUG:** Enoxaparin

## Key facts

- **NCT ID:** NCT03363035
- **Lead sponsor:** Second Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-15
- **Primary completion:** 2021-11-11
- **Final completion:** 2021-11-30
- **Target enrollment:** 2055 (ACTUAL)
- **Last updated:** 2022-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03363035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03363035, "Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03363035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*